| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib,...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of NewAmsterdam Pharma Co (NASDAQ:NAMS) through any online brokerage.
Other companies in NewAmsterdam Pharma Co’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
NewAmsterdam Pharma Co has a consensus price target of $46.00.
The stock price for NewAmsterdam Pharma Co (NASDAQ: NAMS) is $19.6221 last updated October 16, 2026 at 4:16 PM EDT.
There are no upcoming dividends for NewAmsterdam Pharma Co.
NewAmsterdam Pharma Co does not have any upcoming earnings scheduled.
There is no upcoming split for NewAmsterdam Pharma Co.
NewAmsterdam Pharma Co is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
